CymaBay Therapeutics, Inc. (NASDAQ: CBAY) Starts Presentation at 29th Annual ROTH Conference
CymaBay Therapeutics (NASDAQ: CBAY) is a clinical-stage biopharmaceutical company developing therapies to treat specialty and orphan diseases with high unmet medical need. Seladelpar is a potent, selective, orally active PPARδ agonist. CymaBay has recently completed a phase 2 study of seladelpar in patients with primary biliary cholangitis as well as a pilot phase 2 study in patients with homozygous familial hypercholesterolemia, establishing proof-of-concept in both indications. For more information, visit the company’s website at www.cymabay.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news…